The AMD3100-3102 study was a multicenter randomized, double-blind, placebo-controlled trial, evaluating the safety and efficacy of plerixafor plus G-CSF versus placebo plus G-CSF in mobilizing HSCs in MM patients. This evidence concerns the gene CSF3 and Miyoshi myopathy.